Trgovina Lyell Immunopharma, Inc. - LYEL CFD
Dodaj med priljubljene- Povzetek
- Zgodovinski podatki
- Dogodki
- Izkaz poslovnega izida
- Bilanca stanja
- Denarni tok
- Lastništvo
Razmik | 0.05 | ||||||||
Nočna pristojbina za nakup
Long position overnight fee
Pojdi na platformo | -0.025457% | ||||||||
Nočna pristojbina za prodajo
Short position overnight fee
Pojdi na platformo | 0.003235% | ||||||||
Čas nočne pristojbine | 21:00 (UTC) | ||||||||
Min. tržena količina | 1 | ||||||||
Valuta | USD | ||||||||
Kritje | 20% | ||||||||
Borza | United States of America | ||||||||
Provizija na trgovanje | 0% |
*Information provided by Capital.com
Lyell Immunopharma Inc ESG Risk Ratings
‘C’ score indicates satisfactory relative ESG performance and moderate degree of transparency in reporting material ESG data publicly.
Predhodno. Zapri* | 3.3 |
Odpri* | 3.37 |
Enoletna sprememba* | -18.4% |
Dnevni razpon* | 3.33 - 3.49 |
Razpon 52 wk | 1.77-8.74 |
Povprečni obseg (10 dni) | 1.24M |
Povprečni obseg (3 meseci) | 22.43M |
Tržna kapitalizacija | 831.20M |
Razmerje P/E | -100.00K |
Število delnic v obtoku | 249.61M |
Prihodki | 84.20M |
EPS | -0.73 |
Dividenda (donosnost v %) | N/A |
Beta | -100.00K |
Datum naslednjega zaslužka | N/A |
Vse podatke je zagotovil Refinitiv, razen podatkov, označenih z zvezdico, ki so *podatki, ki jih je zagotovil Capital.com
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Zapiranje | Change | Change (%) | Odpiranje | High | Low |
---|---|---|---|---|---|---|
Jun 2, 2023 | 3.47 | 0.14 | 4.20% | 3.33 | 3.49 | 3.25 |
Jun 1, 2023 | 3.30 | 0.15 | 4.76% | 3.15 | 3.38 | 2.84 |
May 31, 2023 | 3.18 | 0.44 | 16.06% | 2.74 | 3.19 | 2.74 |
May 30, 2023 | 2.74 | -0.04 | -1.44% | 2.78 | 3.00 | 2.66 |
May 26, 2023 | 2.87 | 0.09 | 3.24% | 2.78 | 2.89 | 2.76 |
May 25, 2023 | 2.82 | 0.08 | 2.92% | 2.74 | 2.88 | 2.74 |
May 24, 2023 | 2.87 | 0.06 | 2.14% | 2.81 | 2.91 | 2.68 |
May 23, 2023 | 2.85 | 0.05 | 1.79% | 2.80 | 2.97 | 2.79 |
May 22, 2023 | 2.86 | 0.13 | 4.76% | 2.73 | 2.94 | 2.73 |
May 19, 2023 | 2.73 | 0.28 | 11.43% | 2.45 | 2.74 | 2.45 |
May 18, 2023 | 2.50 | -0.07 | -2.72% | 2.57 | 2.61 | 2.47 |
May 17, 2023 | 2.64 | -0.04 | -1.49% | 2.68 | 2.68 | 2.46 |
May 16, 2023 | 2.68 | -0.22 | -7.59% | 2.90 | 2.90 | 2.67 |
May 15, 2023 | 2.98 | 0.55 | 22.63% | 2.43 | 3.00 | 2.43 |
May 12, 2023 | 2.50 | 0.01 | 0.40% | 2.49 | 2.62 | 2.38 |
May 11, 2023 | 2.49 | -0.05 | -1.97% | 2.54 | 2.64 | 2.43 |
May 10, 2023 | 2.58 | 0.15 | 6.17% | 2.43 | 2.60 | 2.41 |
May 9, 2023 | 2.43 | 0.24 | 10.96% | 2.19 | 2.47 | 2.19 |
May 8, 2023 | 2.27 | -0.11 | -4.62% | 2.38 | 2.44 | 2.14 |
May 5, 2023 | 2.45 | 0.05 | 2.08% | 2.40 | 2.54 | 2.37 |
Lyell Immunopharma, Inc. Events
Čas (UTC) (UTC) | Država | Dogodek |
---|---|---|
No events scheduled |
- Letni
- Četrtletno
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Skupni prihodki | 84.683 | 10.65 | 7.756 | 0.657 |
Prihodki | 84.683 | 10.65 | 7.756 | 0.657 |
Celotni odhodki iz poslovanja | 276.741 | 261.873 | 219.693 | 102.746 |
Celotna prodaja/splošni/upravni stroški Odhodki | 117.307 | 89.057 | 46.881 | 39.151 |
Raziskave in razvoj | 164.318 | 134.98 | 182.243 | 63.595 |
Other Operating Expenses, Total | -9.884 | 1.089 | -9.431 | 0 |
Prihodki iz poslovanja | -192.058 | -251.223 | -211.937 | -102.089 |
Prihodki (odhodki) od obresti, neto Neoperativni | 5.986 | 0.909 | 5.939 | 8.121 |
Drugo, neto | 2.954 | 0.095 | 1.526 | -35.409 |
Čisti dobiček pred obdavčitvijo | -183.118 | -250.219 | -204.472 | -129.377 |
Čisti dobiček po davkih | -183.118 | -250.219 | -204.472 | -129.377 |
Čisti dobiček pred dodatnimi postavkami | -183.118 | -250.219 | -204.472 | -129.377 |
Čisti dobiček | -183.118 | -250.219 | -204.472 | -129.377 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -183.118 | -250.219 | -204.472 | -129.377 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -183.118 | -250.219 | -204.472 | -129.377 |
Popravljen čisti dobiček | -183.118 | -250.219 | -204.472 | -129.377 |
Popravljene ponderirane povprečne delnice | 249.567 | 242.738 | 242.83 | 242.83 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.73374 | -1.03082 | -0.84204 | -0.53279 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | ||
Popravljen normalizirani dobiček na enoto čistega dobička | -0.71371 | -0.87943 | -0.84204 | -0.53279 |
Nenavadni odhodki (prihodki) | 5 | 36.747 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Skupni prihodki | 0.065 | 48.386 | 0.003 | 35.741 | 0.553 |
Prihodki | 0.065 | 48.386 | 0.003 | 35.741 | 0.553 |
Celotni odhodki iz poslovanja | 72.621 | 63.17 | 71.44 | 73.002 | 69.129 |
Celotna prodaja/splošni/upravni stroški Odhodki | 19.279 | 26.348 | 26.084 | 30.454 | 34.421 |
Raziskave in razvoj | 46.338 | 45.339 | 39.166 | 40.132 | 39.681 |
Other Operating Expenses, Total | -2.996 | -8.517 | 1.19 | 2.416 | -4.973 |
Prihodki iz poslovanja | -72.556 | -14.784 | -71.437 | -37.261 | -68.576 |
Prihodki (odhodki) od obresti, neto Neoperativni | 4.497 | 3.453 | 1.17 | 0.938 | 0.425 |
Drugo, neto | 1.1 | 2.934 | 0.013 | 0.007 | |
Čisti dobiček pred obdavčitvijo | -66.959 | -8.397 | -70.254 | -36.323 | -68.144 |
Čisti dobiček po davkih | -66.959 | -8.397 | -70.254 | -36.323 | -68.144 |
Čisti dobiček pred dodatnimi postavkami | -66.959 | -8.397 | -70.254 | -36.323 | -68.144 |
Čisti dobiček | -66.959 | -8.397 | -70.254 | -36.323 | -68.144 |
Prihodek, ki je na razpolago navadnim delničarjem, brez dodatnih postavk | -66.959 | -8.397 | -70.254 | -36.323 | -68.144 |
Prihodek, ki je na razpolago skupnemu dobičku, vključno z dodatnimi postavkami | -66.959 | -8.397 | -70.254 | -36.323 | -68.144 |
Popravljen čisti dobiček | -66.959 | -8.397 | -70.254 | -36.323 | -68.144 |
Popravljene ponderirane povprečne delnice | 249.591 | 259.414 | 248.32 | 246.312 | 244.178 |
Popravljen dobiček na delnico brez upoštevanja izrednih postavk | -0.26827 | -0.03237 | -0.28292 | -0.14747 | -0.27908 |
Dividends per Share - Common Stock Primary Issue | 0 | 0 | 0 | 0 | |
Popravljen normalizirani dobiček na enoto čistega dobička | -0.22821 | -0.03237 | -0.26278 | -0.14747 | -0.27908 |
Nenavadni odhodki (prihodki) | 10 | 0 | 5 |
- Letni
- Četrtletno
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Kratkoročna sredstva skupaj | 651.295 | 626.286 | 617.547 | 440.259 |
Denarna sredstva in kratkoročne naložbe | 640.152 | 614.794 | 612.619 | 436.049 |
Denarna sredstva in ustrezniki | 123.554 | 293.828 | 140.406 | 96.674 |
Kratkoročne naložbe | 516.598 | 320.966 | 472.213 | 339.375 |
Prepaid Expenses | 11.143 | 11.492 | 4.928 | 4.21 |
Total Assets | 937.561 | 1127.41 | 908.28 | 555.631 |
Property/Plant/Equipment, Total - Net | 166.265 | 166.639 | 124.055 | 43.705 |
Property/Plant/Equipment, Total - Gross | 198.649 | 181.152 | 129.159 | 44.961 |
Accumulated Depreciation, Total | -32.384 | -14.513 | -5.104 | -1.256 |
Long Term Investments | 115.041 | 330.532 | 163.443 | 68.983 |
Other Long Term Assets, Total | 4.96 | 3.949 | 3.235 | 2.684 |
Total Current Liabilities | 37.028 | 46.738 | 49.285 | 22.045 |
Accounts Payable | 3.917 | 3.207 | 9.396 | 2.844 |
Accrued Expenses | 26.403 | 27.588 | 26.952 | 13.019 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 6.708 | 15.943 | 12.937 | 6.182 |
Total Liabilities | 104.309 | 197.619 | 189.84 | 147.576 |
Total Long Term Debt | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 67.281 | 150.881 | 140.555 | 125.531 |
Total Equity | 833.252 | 929.787 | 718.44 | 408.055 |
Redeemable Preferred Stock | 0 | 0 | 1010.97 | 519.163 |
Common Stock | 0.025 | 0.024 | 0.002 | 0.001 |
Additional Paid-In Capital | 1608.31 | 1515.75 | 41.357 | 18.108 |
Retained Earnings (Accumulated Deficit) | -767.48 | -584.362 | -334.143 | -129.671 |
Other Equity, Total | -7.599 | -1.623 | 0.256 | 0.454 |
Total Liabilities & Shareholders’ Equity | 937.561 | 1127.41 | 908.28 | 555.631 |
Total Common Shares Outstanding | 249.567 | 242.738 | 242.83 | 242.83 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Kratkoročna sredstva skupaj | 624.398 | 651.295 | 659.745 | 666.778 | 625.705 |
Denarna sredstva in kratkoročne naložbe | 612.769 | 640.152 | 648.132 | 655.564 | 613.912 |
Denarna sredstva in ustrezniki | 109.426 | 123.554 | 116.311 | 205.739 | 222.596 |
Kratkoročne naložbe | 503.343 | 516.598 | 531.821 | 449.825 | 391.316 |
Prepaid Expenses | 11.629 | 11.143 | 11.613 | 11.214 | 11.793 |
Total Assets | 880.45 | 937.561 | 977.269 | 1021.67 | 1072.1 |
Property/Plant/Equipment, Total - Net | 160.99 | 166.265 | 169.811 | 172.466 | 171.432 |
Long Term Investments | 90.179 | 115.041 | 144.52 | 178.439 | 271.119 |
Other Long Term Assets, Total | 4.883 | 4.96 | 3.193 | 3.991 | 3.847 |
Total Current Liabilities | 30.797 | 37.028 | 51.217 | 50.291 | 41.055 |
Accounts Payable | 5.733 | 3.917 | 4.795 | 4.247 | 6.51 |
Accrued Expenses | 22.416 | 28.755 | 23.568 | 21.396 | 22.686 |
Notes Payable/Short Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Current Liabilities, Total | 2.648 | 4.356 | 22.854 | 24.648 | 11.859 |
Total Liabilities | 96.624 | 104.309 | 157.243 | 153.632 | 190.854 |
Total Long Term Debt | 0 | 0 | 0 | 0 | 0 |
Other Liabilities, Total | 65.827 | 67.281 | 106.026 | 103.341 | 149.799 |
Total Equity | 783.826 | 833.252 | 820.026 | 868.042 | 881.249 |
Redeemable Preferred Stock | 0 | 0 | 0 | 0 | 0 |
Common Stock | 0.025 | 0.025 | 0.025 | 0.025 | 0.025 |
Additional Paid-In Capital | 1622.12 | 1608.31 | 1589.08 | 1565.2 | 1540.33 |
Retained Earnings (Accumulated Deficit) | -834.439 | -767.48 | -759.083 | -688.829 | -652.506 |
Other Equity, Total | -3.879 | -7.599 | -9.996 | -8.351 | -6.6 |
Total Liabilities & Shareholders’ Equity | 880.45 | 937.561 | 977.269 | 1021.67 | 1072.1 |
Total Common Shares Outstanding | 249.609 | 249.567 | 249.24 | 247.11 | 245.423 |
- Letni
- Četrtletno
2022 | 2021 | 2020 | 2019 | |
---|---|---|---|---|
Čisti prihodki/začetna postavka | -183.118 | -250.219 | -204.472 | -129.377 |
Denarna sredstva iz poslovanja | -169.555 | -126.249 | -160.874 | 39.474 |
Denarna sredstva iz poslovanja | 18.02 | 13.624 | 4.294 | 1.256 |
Nedenarne postavke | 77.558 | 106.331 | 39.64 | 56.787 |
Spremembe v obratnem kapitalu | -82.015 | 4.015 | -0.336 | 110.808 |
Denarna sredstva pri naložbenju | -11.54 | -121.573 | -273.516 | -422.433 |
Kapitalski izdatki | -24.276 | -65.504 | -51.481 | -16.047 |
Celotne druge postavke denarnih tokov pri naložbenju | 12.736 | -56.069 | -222.035 | -406.386 |
Denarna sredstva pri financiranju | 10.635 | 401.244 | 476.79 | 351.156 |
Izdaja (odplačilo) delnic, neto | 11.096 | 401.244 | 476.79 | 351.156 |
Neto sprememba denarnih sredstev | -170.46 | 153.422 | 42.4 | -31.803 |
Postavke denarnega toka pri financiranju | -0.461 |
Mar 2023 | Dec 2022 | Sep 2022 | Jun 2022 | Mar 2022 | |
---|---|---|---|---|---|
Net income/Starting Line | -66.959 | -183.118 | -174.721 | -104.467 | -68.144 |
Cash From Operating Activities | -46.212 | -169.555 | -129.288 | -92.185 | -47.852 |
Cash From Operating Activities | 5.027 | 18.02 | 12.979 | 8.358 | 4.187 |
Non-Cash Items | 20.031 | 77.558 | 71.076 | 44.295 | 18.494 |
Changes in Working Capital | -4.311 | -82.015 | -38.622 | -40.371 | -2.389 |
Cash From Investing Activities | 32.154 | -11.54 | -58.188 | -1.103 | -26.122 |
Capital Expenditures | -1.533 | -24.276 | -19.694 | -16.903 | -9.733 |
Other Investing Cash Flow Items, Total | 33.687 | 12.736 | -38.494 | 15.8 | -16.389 |
Cash From Financing Activities | -0.069 | 10.635 | 9.772 | 5.012 | 2.555 |
Issuance (Retirement) of Stock, Net | 0 | 11.096 | 10.139 | 5.012 | 2.555 |
Net Change in Cash | -14.127 | -170.46 | -177.704 | -88.276 | -71.419 |
Financing Cash Flow Items | -0.069 | -0.461 | -0.367 |
Ime vlagatelja | Vrsta vlagatelja | Odstotek neporavnanih obveznosti | Delnice v lasti | Sprememba delnic | Datum imetništva | Ocena prometa |
---|---|---|---|---|---|---|
ARCH Venture Partners | Venture Capital | 14.5879 | 36412716 | 0 | 2023-03-31 | LOW |
GSK plc | Corporation | 12.1202 | 30253189 | 0 | 2023-03-31 | MED |
MWG Management, Ltd. | Investment Advisor | 8.0776 | 20162332 | 0 | 2023-03-31 | LOW |
Apoletto Ltd | Investment Advisor | 6.047 | 15093969 | 0 | 2022-09-30 | LOW |
Orland Properties Ltd | Investment Advisor | 6.047 | 15093969 | 0 | 2023-03-31 | LOW |
The Vanguard Group, Inc. | Investment Advisor/Hedge Fund | 5.1116 | 12759123 | 167893 | 2023-03-31 | LOW |
BlackRock Institutional Trust Company, N.A. | Investment Advisor | 4.2214 | 10537077 | 146262 | 2023-03-31 | LOW |
Foresite Capital Management, LLC | Private Equity | 4.0063 | 10000000 | 0 | 2023-03-31 | LOW |
State Street Global Advisors (US) | Investment Advisor/Hedge Fund | 3.1735 | 7921252 | -829167 | 2023-03-31 | LOW |
Alphabet, Inc. | Venture Capital | 2.3497 | 5865125 | 0 | 2023-03-31 | LOW |
Bishop (Hans Edgar) | Individual Investor | 1.8772 | 4685614 | 0 | 2023-03-31 | LOW |
Klausner Richard | Individual Investor | 1.5852 | 3956734 | -11100 | 2023-03-31 | LOW |
T. Rowe Price Associates, Inc. | Investment Advisor | 1.5761 | 3934038 | 288326 | 2023-03-31 | LOW |
Geode Capital Management, L.L.C. | Investment Advisor/Hedge Fund | 1.2774 | 3188435 | 136430 | 2023-03-31 | LOW |
MIC Capital Management UK LLP | Investment Advisor | 1.2261 | 3060569 | 0 | 2023-03-31 | LOW |
SC China Holding Ltd | Investment Advisor | 1.2203 | 3045997 | 0 | 2023-03-31 | LOW |
Fidelity Management & Research Company LLC | Investment Advisor | 1.1739 | 2930205 | -41166 | 2023-03-31 | LOW |
Jacobs Levy Equity Management, Inc. | Investment Advisor/Hedge Fund | 0.6789 | 1694698 | 1658398 | 2023-03-31 | MED |
MFS Investment Management | Investment Advisor/Hedge Fund | 0.5574 | 1391408 | 102881 | 2023-03-31 | LOW |
Northern Trust Investments, Inc. | Investment Advisor/Hedge Fund | 0.5026 | 1254629 | -40550 | 2023-03-31 | LOW |
Zakaj izbrati Capital.com? Številke govorijo same zase.
Capital.com Group535K+
Borzni posredniki
87K+
Aktivne stranke mesečno
$113M+
Mesečni obseg naložb
$64M+
Dvigi vsak mesec
Kalkulator trgovanja
Izračunajte svoj hipotetični P&L, če bi trgovino s CFD odprli na določen datum (izberite datum) in jo zaprli na drug datum (izberite datum).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
Lyell Immunopharma, Inc. Company profile
O družbi Lyell Immunopharma, Inc.
Družba Lyell Immunopharma, Inc. je podjetje za reprogramiranje celic T. Podjetje ponuja celice T za zdravljenje bolnikov s solidnimi tumorji. Njene tehnologije so zasnovane tako, da se ciljno in agnostično uporabljajo za terapije s himeričnimi antigenskimi receptorji (CAR), limfociti, ki infiltrirajo tumor (TIL), in celičnimi receptorji (TCR) za izboljšanje lastnosti celic T za izkoreninjenje solidnih tumorjev. Ustvarja večmodalno linijo izdelkov za indikacije solidnih tumorjev z neizpolnjenimi potrebami in pričakuje, da bo vložil vlogo za novo raziskovalno zdravilo (IND). Ponuja tehnološki platformi Gen-R in Epi-R. Gen-R je tehnologija genskega reprogramiranja ex vivo za premagovanje izčrpanosti celic T. Epi-R je tehnologija epigenetskega reprogramiranja ex vivo za ustvarjanje populacije celic T s trajno matičnostjo. Epi-R je zasnovan za ustvarjanje populacij celic T, ki imajo to lastnost trajne matičnosti. Podjetje uporablja svoji tehnološki platformi Gen-R in Epi-R za razvoj večmodalnega proizvodnega programa.
Industry: | Bio Therapeutic Drugs |
201 Haskins Way
Suite 301
SOUTH SAN FRANCISCO
CALIFORNIA 94080
US
Izkaz poslovnega izida
- Annual
- Quarterly
Ljudje gledajo tudi
Še vedno iščete posrednika, ki mu lahko zaupate?
Pridružite se 535.000+ trgovcem po vsem svetu, ki so se odločili za trgovanje s Capital.com